David Rawling,
Senior Principal Scientist
Dr. David Rawling is the Director of Assay Research and Development at Inflammatix, Inc., a molecular diagnostics company currently focused on host response-based diagnostics for sepsis and infectious diseases. He received his Ph.D. in Molecular Biophysics and Biochemistry from Yale University, where he focused on host-pathogen interactions and assay development for novel compound discovery. Dr. Rawling completed post-doctoral work at Cepheid, Inc. where he focused on rare mutation detection in circulating tumor cells and interrogating oncogene methylation states for diagnostic applications. Dr. Rawling's research is focused on translating emerging amplification and detection technologies to microfluidic, sample-to-answer platforms.
|
|
|
